Globe Newswire Saint-Herblain (France), September 12, 2024 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) ( Valneva or the Company ), a specialty vaccine company, today announces its intention to issue, subject...\n more…
Globe Newswire VLA15-221 Phase 2 study: strong immune response shown one month after a second booster dose (month 31) in pediatric and adult populationsSignificant anamnestic antibody response observed across all...\n more…
Zacks Investment Research Shares of Valneva SE Sponsored ADR (VALN) have gained 3.5% over the past four weeks to close the last trading session at $7.32, but there could still be a solid upside left in the stock if short-term...\n more…
Ticker Report Valneva SE (NASDAQ:VALN - Free Report) - Equities research analysts at HC Wainwright increased their Q3 2024 earnings per share (EPS) estimates for Valneva in a research report issued to clients and...\n more…
Zacks Investment Research Valneva SE Sponsored ADR (VALN) closed the last trading session at $7.79, gaining 0.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set...\n more…